Zaltrap
E823215
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
VEGF inhibitor
ⓘ
angiogenesis inhibitor ⓘ anti‑cancer drug ⓘ brand name drug ⓘ pharmaceutical drug ⓘ |
| administrationSchedule | every 2 weeks in combination with FOLFIRI ⓘ |
| approvalBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIn |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| brandNameOf | aflibercept NERFINISHED ⓘ |
| coDevelopedBy | Sanofi NERFINISHED ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
hypertension ⓘ neutropenia ⓘ proteinuria ⓘ stomatitis ⓘ |
| contraindication | severe hypersensitivity to aflibercept ⓘ |
| developedBy | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| firstApprovalYear | 2012 ⓘ |
| hasActiveIngredient | aflibercept NERFINISHED ⓘ |
| hasATCCode | L01XX44 NERFINISHED ⓘ |
| hasBlackBoxWarning |
compromised wound healing
ⓘ
gastrointestinal perforation ⓘ hemorrhage ⓘ |
| hasDosageForm | concentrate for solution for infusion ⓘ |
| indicatedForUseIn | adults ⓘ |
| indication | treatment of metastatic colorectal cancer resistant to or progressed after oxaliplatin-containing therapy ⓘ |
| legalStatus | prescription only ⓘ |
| marketedBy | Sanofi NERFINISHED ⓘ |
| mechanismOfAction |
acts as a soluble decoy receptor for VEGF
ⓘ
inhibits angiogenesis by binding VEGF ⓘ |
| notIndicatedFor | pediatric patients ⓘ |
| originatorCompany | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| pharmacologicalClass |
anti‑VEGF agent
ⓘ
recombinant fusion protein ⓘ |
| pregnancyCategory | can cause fetal harm ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
VEGF-A
NERFINISHED
ⓘ
VEGF-B ⓘ placental growth factor ⓘ vascular endothelial growth factor ⓘ |
| therapeuticArea | oncology ⓘ |
| treats |
colorectal cancer
ⓘ
metastatic colorectal cancer ⓘ |
| usedInCombinationWith |
FOLFIRI
NERFINISHED
ⓘ
chemotherapy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.